Cargando…
Leber’s hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation
PURPOSE: In September 2015, the first and so far only medication for treatment of Leber’s hereditary optic neuropathy (LHON) was approved in the EU. The drug in question is idebenone (©Raxone) and has been given to all newly diagnosed patients of the University Eye Hospital Tuebingen since the appro...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016777/ https://www.ncbi.nlm.nih.gov/pubmed/33337510 http://dx.doi.org/10.1007/s00417-020-05045-4 |